ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy - Wikidata - wikimedia - TriplyDB

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy

http://www.wikidata.org/entity/Q33476874

about

p38MAPK and Chemotherapy: We Always Need to Hear Both Sides of the Story Redundancy in the World of MAP Kinases: All for One MicroRNAs mediated regulation of MAPK signaling pathways in chronic myeloid leukemia CM363, a novel naphthoquinone derivative which acts as multikinase modulator and overcomes imatinib resistance in chronic myelogenous leukemia Forced expression of cyclin-dependent kinase 6 confers resistance of pro-B acute lymphocytic leukemia to Gleevec treatment Snail promotes epithelial mesenchymal transition in breast cancer cells in part via activation of nuclear ERK2.A therapeutically targetable mechanism of BCR-ABL-independent imatinib resistance in chronic myeloid leukemia.Using functional genomics to overcome therapeutic resistance in hematological malignancies.MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.MAPK15 mediates BCR-ABL1-induced autophagy and regulates oncogene-dependent cell proliferation and tumor formation.Small G proteins Rac1 and Ras regulate serine/threonine protein phosphatase 5 (PP5)·extracellular signal-regulated kinase (ERK) complexes involved in the feedback regulation of Raf1.Regulation of mammalian target of rapamycin and mitogen activated protein kinase pathways by BCR-ABL.Current status of agents active against the T315I chronic myeloid leukemia phenotype.Grb10 is involved in BCR-ABL-positive leukemia in mice.Contributions of MET activation to BCR-ABL1 tyrosine kinase inhibitor resistance in chronic myeloid leukemia cells.Novel Molecular Challenges in Targeting Anaplastic Lymphoma Kinase in ALK-Expressing Human Cancers.KPT-330 inhibition of chromosome region maintenance 1 is cytotoxic and sensitizes chronic myeloid leukemia to Imatinib.

P2860

Q26742078-F9BCE00B-D0DB-4FCB-B142-F33170CF8E80 Q26742080-34C1F9A4-689C-49EE-B0D9-38E4AEED48E5 Q26766288-5AE86178-D5CD-42EB-84FE-F51156B7CB20 Q33728096-4AB6DCD4-0C06-47DA-A77E-52A9136BACE4 Q33887799-385D78EE-B4DB-437D-9C3E-CA37A9C53E0E Q34047362-D240EC1E-5A05-4151-8DAE-3B23C7C6E507 Q34170309-AC8BDF87-CAEC-463F-972E-5278CF37D011 Q34401328-5102B8F0-CD10-459F-9DBB-6A1BA5067D69 Q35905629-00DE0394-E07D-492C-8464-6BDBD099A6D9 Q36777169-749BE20A-698D-43F5-94A9-2B4965564250 Q37583522-0AA7489F-4BEC-458A-BC78-903BBD279C64 Q37836931-8105F430-9C44-4A5B-BFF5-64BC04537FAF Q37847179-8C7F758D-E148-475A-A249-18B7713D0A9D Q38953915-49D3D24E-63E7-4F0B-A7A0-72DE548ABEE1 Q40971143-A3A8457A-83D4-41DA-A854-D3213F6F92D5 Q47134648-2D65717B-78E8-46B7-AE56-4325C706F55B Q52715766-384BF884-83BE-46CF-9D4A-51B4A90E09CF

P2860

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy

http://www.wikidata.org/entity/Q33476874

description

2009 nî lūn-bûn

@nan

2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

ERK2, but not ERK1, mediates a ...... e: implication for CML therapy

@ast

ERK2, but not ERK1, mediates a ...... e: implication for CML therapy

@en

type

label

ERK2, but not ERK1, mediates a ...... e: implication for CML therapy

@ast

ERK2, but not ERK1, mediates a ...... e: implication for CML therapy

@en

prefLabel

ERK2, but not ERK1, mediates a ...... e: implication for CML therapy

@ast

ERK2, but not ERK1, mediates a ...... e: implication for CML therapy

@en

P1433

Q33476874-94EFCA27-A276-4359-9EF3-5371D313A2FF

P1476

Q33476874-7BA5AFB1-181B-4744-AB6F-9FF32E987FAD

P2093

Q33476874-0AD63CDE-1DDD-45AC-9AD1-957390E0F42D

Q33476874-172192D6-012B-4395-8D6C-792613673523

Q33476874-1C2CE870-9D2B-4F0A-96B5-A666700BCBE8

Q33476874-31661B7A-8435-4343-AD3B-71044C64F677

Q33476874-33996F21-193C-4DE1-AA0E-F37EF4C08376

Q33476874-397921C7-F152-44A3-9DDC-FE9B284EE725

Q33476874-3EB96C19-E92B-4705-947C-C039D84101E6

Q33476874-7DE0B56E-AAAA-4039-93F6-6FBCA5292641

Q33476874-A920F98B-716D-4E70-BEDE-3FA90D6BA2DC

Q33476874-AA9F0873-8991-4965-A815-6D1134A57166

P2860

Q33476874-1944A481-4F8D-4CFA-A9E6-51C4D7923FD0

Q33476874-228ED9FF-6C33-4610-BA53-87D31FF49D0B

Q33476874-2305903B-3A8A-4BC9-B040-6A9AF2953367

Q33476874-2976C2DC-7BDC-44B9-89B3-6AD10194C509

Q33476874-2AD5EEE7-63BD-4C48-9483-3B4C8BB79F63

Q33476874-2D353107-DBCC-49BB-847E-ACEF679D9D06

Q33476874-2F3BA069-EAD4-4582-86FB-98915691B92C

Q33476874-31783B4C-B08B-48E1-8706-ADB6A89C801A

Q33476874-3BE72FB9-245F-4A99-BCE8-0417CCFB1C39

Q33476874-3C85BC95-1763-4350-A016-3B164FA4005F

P304

Q33476874-F76A0951-AEE5-46E9-B0BE-EB226627FE8F

P31

Q33476874-A239D089-5E6A-4E46-8818-92005D0B380A

P356

Q33476874-45C9D35A-EDE9-4F7F-ACE2-D4624A0E1CC5

P407

Q33476874-099789D3-FFA2-45C2-B032-67D67C7A87EB

P433

Q33476874-B7504E6C-3442-451A-8388-A7B2306B9429

P478

Q33476874-51F7B501-A2FA-4472-B874-14A59A3D4DF8

P50

Q33476874-3B47E2B1-6302-421B-AE2D-73060F8BD2F3

Q33476874-86741875-4E4E-4D1D-A119-7D5D45104853

P577

Q33476874-2F950FFF-2CA9-43A9-B9FE-93D7033FD11C

P5875

Q33476874-FEA50405-894B-47BA-A3A6-AA018DE9D46B

P698

Q33476874-A4F6E752-A78E-4234-B321-BF8C92308D10

P932

Q33476874-9D8D6BE2-7038-4B36-9897-F0917CDF7F7B

P356

JOURNAL.PONE.0006124

P1433

P1476

ERK2, but not ERK1, mediates a ...... e: implication for CML therapy

@en

P2093

Anupriya Agarwal

http://www.w3.org/2001/XMLSchema#string

Atanasio Pandiella

http://www.w3.org/2001/XMLSchema#string

Clara I Aceves-Luquero

http://www.w3.org/2001/XMLSchema#string

Eva M Galán Moya

http://www.w3.org/2001/XMLSchema#string

Inmaculada Moreno Gimeno

http://www.w3.org/2001/XMLSchema#string

Itxaso Bellón-Echeverria

http://www.w3.org/2001/XMLSchema#string

Juan C Gómez

http://www.w3.org/2001/XMLSchema#string

Juan L Callejas-Valera

http://www.w3.org/2001/XMLSchema#string

Laura Arias-González

http://www.w3.org/2001/XMLSchema#string

Luis del Peso Ovalle

http://www.w3.org/2001/XMLSchema#string

P2860

Erk5 participates in neuregulin signal transduction and is constitutively active in breast cancer cells overexpressing ErbB2

Critical role for Gab2 in transformation by BCR/ABL

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

Phosphatidylinositol-3-OH kinase as a direct target of Ras

SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin-1

Transforming genes in chronic myelogenous leukemia.

The Erk2 MAPK regulates CD8 T cell proliferation and survival.

Abl-kinase-sensitive levels of ERK5 and its intrinsic basal activity contribute to leukaemia cell survival

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia.

Chronic myeloid leukaemia as a model of disease evolution in human cancer.

P304

e6124

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0006124

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Azucena Esparís-Ogando

Miguel A De la Cruz-Morcillo

P577

2009-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26332279

http://www.w3.org/2001/XMLSchema#string

P698

19568437

http://www.w3.org/2001/XMLSchema#string

P932

2699476

http://www.w3.org/2001/XMLSchema#string